Gynecologic Cancer Program Clinical Trials
A clinical trial is one of the final steps in a long and careful cancer research process that is looking for better ways to prevent, diagnose, or treat cancer. Clinical trials test new medical approaches in patients with cancer, and are important to developing new treatments for cancer. Many of the "standard treatments" that patients with cancer receive today were developed based on the results of previous clinical trials.
The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you.
Cervix Clinical Trials
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Other Urinary Clinical Trials
Immunologic Evaluation of Peripheral Blood
Ovary Clinical Trials
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer NCT # NCT02101788
A Randomized, Double-Blind, Placebo Controlled Phase II/III Trial of Vigil(tm) Augmented Autologous Tumor Cell Immunotherapy in Subjects with Stage III/IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy (VITAL)
A randomized phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Uterus Clinical Trials
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC# 91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer NCT #02065687